*Wegovy, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI 30 kg/m 2 ), or overweight (BMI27 kg/m 2 ) with at least one weight related comorbidity
Some people notice digestive symptoms shortly after beginning treatment
Lyophilized Ipamorelin is shipped at ambient temperature in protective packaging
Sample Size: 125,474 adults T2DM (61.0% of total sample, n = 76,524) 98.6% (n = 75,434) using GLP-1s as antidiabetic medications 1.4% (n = 1,090) using GLP-1s as antiobesity medications Without T2DM (39.0% of total sample, n = 48,950) 61.8% (n = 30,236) using GLP-1s off-label as antidiabetic medications 38.2% (n = 18,714) using GLP-1s specifically for weight management Data Source: Truveta Data Aggregated electronic health record (EHR) data from 30 U.S
Could pills work instead